Stock Price & Analysis

The S1 support level for DERM Stock is $3.58 ,The R1 resistant level for DERM Stock is $4.28.

As of the end of day on 2025-01-22, the price of DERM Stock was $3.84.

The target price for DERM Stock according to analyst rating is 9.67, with the highest price target at 11.00 and the lowest at 9.00. Analysts have a Strong Buy rating on DERM Stock overall.

The market cap of DERM is $54.8M.

Journey Medical Corporation is a pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes over eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products that have been approved by the United States Food and Drug Administration (FDA) for sale include Qbrexza, Accutane, Targadox, Ximino, and Exelderm Cream and Solution. The Company's product Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, which is an oral isotretinoin drug for the treatment of severe recalcitrant severe acne; Targadox, which is an oral doxycycline drug for adjunctive therapy for acne; Ximino, which is an oral minocycline drug for the treatment of moderate to severe acne, and Exelderm Cream and Solution is an antifungal intended for topical use.

DERM has a total of 58 employees.